Researchers Identify New Cancer Metastasis-Suppressor Gene

Share this article:

the ONA take:

Researchers searching for a target that would interfere with cancer metastasis identified a new suppressor of metastasis that may lead toward the development of more effective treatments for prostate cancer and other malignant solid tumors. More than 90% of patients with deadly cancers die because of metastatic spread of their disease. Activation of the PI3K/AKT signal pathway is known to drive prostate cancer progression to the castrate-resistant stage. A research team at Roswell Park Cancer Institute (RPCI) identified a previously unknown metastasis suppressor, the FOXO4 protein, which belongs to a family of genes that are produced by all cells. The team demonstrated that FOXO4 works to prevent the spread of cancerous tumors by binding to and inhibiting the protein RUNX2, and in doing so, identified a circuit that controls metastatic progression in prostate cancer. The research team is now working with collaborators at the University of Maryland to test the effectiveness of an experimental agent that inhibits the RUNX2 function in preventing or impeding prostate cancer metastasis.

Researchers Identify New Cancer Metastasis-Suppressor Gene
Researchers Identify New Cancer Metastasis-Suppressor Gene
— Among patients with deadly cancers, more than 90 percent die because of metastatic spread of their disease. Gelman, Ph.D., of Roswell Park Cancer Institute (RPCI) has identified a new suppressor of cancer metastasis that may point the way toward development of more effective treatments for prostate cancers and other malignant solid tumors.
READ FULL ARTICLE From Newswise
Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in News

Early palliative care reduces hospital readmissions by 23% for patients with cancer

Early palliative care reduces hospital readmissions by 23% ...

Researchers designed a collaborative approach in cancer care that decreased the number of patients readmitted.

For nonadherent patients, individualized testing does not increase colorectal cancer screening rates

For nonadherent patients, individualized testing does not increase ...

Patients who know individual risk for colorectal cancer are not sufficient to convince previously nonadherent patients.

For patients with low-risk prostate cancer managed with active surveillance, obesity may increase risk of progression

For patients with low-risk prostate cancer managed with ...

Obesity is linked with increased risk of progression of low-risk prostate cancers in active surveillance.